Press Releases

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, today announces that it will host a conference call at 10:00 AM Eastern Time on... (continue reading...)

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lincoln National Corporation (NYSE: LNC) between November 4, 2020 and November 2, 2022, both dates inclusive (the “Class Period”), of the important June 24, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Lincoln National securities during the Class Period you may be entitled to compensation without payment of any out... (continue reading...)

Following Pressure from Teamsters, Legislation Passes Both Chambers

MONTPELIER, Vt., May 9, 2024 /PRNewswire/ -- The Teamsters commended the Vermont Senate today for passing the Vermont PRO Act (S. 102), legislation that would make it easier for both private and public sector workers to unionize by expanding the right to form a union to historically marginalized workers. The Vermont PRO Act also protects employees from anti-union captive audience meetings and... (continue reading...)

Calgary, Alberta--(Newsfile Corp. - May 9, 2024) - Baytex Energy Corp. (TSX: BTE) (NYSE: BTE) reports that all matters presented for approval at the annual meeting of shareholders held today were approved. A total of 316,924,889 common shares being 38.56% of Baytex's issued and outstanding shares were represented at the meeting.

At the meeting, all of the nominees proposed as directors were duly elected. Results of the vote are set out below:

• Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab)
• Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients

JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC).... (continue reading...)